Source: International Congress 2014 – Rationale behind respiratory drug development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Vogelmeier, R. Buhl, C. P. Criée, P. Kardos, H. Worth (Marburg, Mainz, Bovenden, Frankfurt am Main, Fuerth, Germany). Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort. Eur Respir J 2014; 44: Suppl. 58, 930

Member's Comments

No comment yet.

Related content which might interest you: What are common COPD symptoms in a real-life setting? The German DACCORD registry Source: International Congress 2014 – COPD markers Year: 2014 Effectiveness of self-treatment of exacerbations in COPD patients: Two-year follow-up of the COPE-II study Source: International Congress 2014 – Best abstracts in rehabilitation and chronic care (sponsored by MOTEK Medical) Year: 2014 Effectiveness of a comprehensive management program of fragile COPD patients Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD Year: 2014 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Distribution and outcomes of the new Spanish phenotype-based guideline for COPD Source: International Congress 2014 – COPD exacerbations Year: 2014 Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Tele-monitoring intervention on COPD exacerbations Source: International Congress 2016 – Novel approaches for pulmonary rehabilitation in chronic lung diseases Year: 2016 COPD telemonitoring: Analysis of hospital admissions Source: International Congress 2014 – Monitoring COPD with different biomarkers Year: 2014 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Hospital treatment costs of exacerbations in COPD patients with indications for LTOT Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Exacerbations and healthcare resource utilization among COPD patients in Sweden Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Impact of mucolytic treatment on COPD exacerbations Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014